Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
2014 · Journal of Hematology & Oncology · 189 citations
https://doi.org/10.1186/1756-8722-7-1
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
12
Papers
469
Citations
7
h-index
6
i10-index
Joanna Vitfell-Rasmussen is an academic researcher. The author has contributed to research in topics: Radiopharmaceutical Chemistry and Applications & Medical Imaging Techniques and Applications & Heat shock proteins research. The author has an h-index of 7, co-authored 11 publications.
ORCID: 0000-0003-0983-0732Click to start Chat